https://www.selleckchem.com/pr....oducts/bms-986158.ht
Neratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C versus lapatinib + capecitabine (L+C) in 621 patients with HER2+ metastatic breast cancer (MBC) who had received greater than or equal to2 prior HER2-directed regimens in the metastatic setting. We evaluated correlations between exploratory biomarkers and PFS. Somatic mutations were evaluated by next-generation sequencing on primary or metastatic samples. HER2 protein exp
Curtir
Comentario
Compartilhar
